GRI Bio, Inc. (GRI)
1.80
-0.03
(-1.64%)
USD |
NASDAQ |
Nov 12, 16:00
1.80
0.00 (0.00%)
After-Hours: 18:51
GRI Bio Enterprise Value : -6.902M for Nov. 11, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 11, 2026 | -6.902M |
| November 10, 2026 | -6.771M |
| November 09, 2026 | -7.165M |
| November 06, 2026 | -6.793M |
| November 05, 2026 | -7.514M |
| November 04, 2026 | -7.777M |
| November 03, 2026 | -7.536M |
| November 02, 2026 | -7.711M |
| October 30, 2026 | -7.558M |
| October 29, 2026 | -7.471M |
| October 28, 2026 | -7.351M |
| October 27, 2026 | -7.449M |
| October 26, 2026 | -7.624M |
| October 23, 2026 | -7.733M |
| October 22, 2026 | -7.799M |
| October 21, 2026 | -7.689M |
| October 20, 2026 | -7.711M |
| October 19, 2026 | -7.733M |
| October 16, 2026 | -7.886M |
| October 15, 2026 | -7.842M |
| October 14, 2026 | -7.842M |
| October 13, 2026 | -7.514M |
| October 12, 2026 | -7.471M |
| October 09, 2026 | -7.099M |
| October 08, 2026 | -7.230M |
| Date | Value |
|---|---|
| October 07, 2026 | -6.859M |
| October 06, 2026 | -6.749M |
| October 05, 2026 | -6.728M |
| October 02, 2026 | -6.618M |
| October 01, 2026 | -6.618M |
| September 30, 2026 | -6.684M |
| September 29, 2026 | -6.531M |
| September 28, 2026 | -6.312M |
| September 25, 2026 | -6.422M |
| September 24, 2026 | -6.334M |
| September 23, 2026 | -6.203M |
| September 22, 2026 | -6.422M |
| September 21, 2026 | -6.662M |
| September 18, 2026 | -6.684M |
| September 17, 2026 | -6.881M |
| September 16, 2026 | -6.946M |
| September 15, 2026 | -6.924M |
| September 14, 2026 | -6.771M |
| September 11, 2026 | -6.749M |
| September 10, 2026 | -6.662M |
| September 09, 2026 | -6.968M |
| September 08, 2026 | -6.531M |
| September 04, 2026 | -4.607M |
| September 03, 2026 | -5.897M |
| September 02, 2026 | -6.531M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.270B |
| Alnylam Pharmaceuticals, Inc. | 20.81B |
| Anika Therapeutics, Inc. | 168.04M |
| Savara, Inc. | 926.34M |
| Vericel Corp. | 2.957B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -1.643M |
| Total Expenses (Quarterly) | 1.643M |
| EPS Diluted (Quarterly) | -0.9103 |
| Earnings Yield | -2.43K% |
| Normalized Earnings Yield | -2430.01 |